Category
Tga
5 articles
TGA Reform Priorities for 2027: Accelerating Access to Medicines for Australians
Australia's Therapeutic Goods Administration faces mounting pressure to modernise its approval pathways, expand biosimilar uptake, close the digital therapeutics regulatory gap, and strengthen post-market surveillance. A policy analysis of the reform agenda for 2027.
GLP-1 Medication Shortage in Australia: Policy Failures, Access Inequity, and the Path to Reform
Australia's GLP-1 receptor agonist shortage exposes deep structural failures in medicines policy. This analysis examines the supply crisis, access inequities, the compounding pharmacy debate, and six concrete reforms needed to ensure equitable access to life-changing obesity and diabetes treatments.
TGA Regulation of Peptides in Australia: What Patients and Clinicians Need to Know
Australia's Therapeutic Goods Administration classifies peptides under a complex scheduling framework. This guide explains TGA peptide schedules, the March 2025 BPC-157 rescheduling, compounding pharmacy access, and what 'research use' means legally.
BPC-157 Schedule 4 in Australia: What the TGA Rescheduling Means and What Comes Next
A detailed policy and science analysis of Australia's TGA decision to reschedule BPC-157 to Schedule 4 in March 2025 — regulatory rationale, clinical implications, and the research evidence for this peptide.
Medicare and PBS Reform for Obesity Treatment: What Australia Needs to Do
Australia's PBS coverage of obesity medications is inadequate, inequitable, and out of step with the clinical evidence. A policy analysis of the case for expanded PBS listing of GLP-1 receptor agonists and what reform should look like.